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evascularization of the
nfarct-Related Artery
ever Too Late to Do Well*
anel Sabaté, MD, PHD, FESC
arcelona, Spain
evascularization of the infarct-related artery (IRA) has
een evaluated since the understanding that an occlusive
hrombus in a coronary artery could be managed either by
hrombolytic therapy or mechanically by means of percuta-
eous coronary interventions (PCIs). However, after acute
yocardial infarction (MI), different scenarios may be
efined according to the duration of the occlusion (Table 1).
uring the early phase of an MI, current consensus is the
eperfusion of the IRA as soon as possible. The main goal in
his phase is myocardial salvage, which is critically time-
ependent. Prompt restoration of blood flow reduces infarct
ize, preserves global left ventricular function, and improves
atient survival. Current guidelines support primary PCI as
he treatment of choice (as opposed to thrombolytic ther-
py) when delivered rapidly and in high-volume centers by
xperienced teams specifically when the time from the onset
See page 956
f symptoms is lower than 12 h. Besides, this technique has
o be performed in a period no longer than 90 min from
atients’ first medical contact (1). Main evidence impacting
his decision comes from a meta-analysis of 23 randomized
rials (2), which together assigned 7,739 thrombolytic-
ligible patients with ST-segment elevation MI to either
rimary PCI or thrombolytic medication. Primary PCI was
etter than thrombolytic therapy at reducing overall short-
erm (defined as 4 to 6 weeks) death (9.3% vs. 7.0%, p 
.0002), nonfatal reinfarction (6.8% vs. 2.5%, p  0.0001),
otal stroke (2.0% vs. 1.0%, p  0.0004), and the combined
nd point of death, nonfatal reinfarction, and stroke (14.5%
s. 8.2%, p 0.0001). During long-term follow-up (6 to 18
onths), the results seen with primary PCI remained better
han those seen with thrombolytic therapy with 12.8%
ersus 9.6% for death, 10.0% versus 4.8% for nonfatal MI,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.1
From the Interventional Cardiology Unit, Cardiology Department, Saint Paul
niversity Hospital, Barcelona, Spain.nd 19% versus 12% for the combined end point of death,
onfatal reinfarction, and stroke. The most impressive
ifference between thrombolysis and primary PCI was the
ignificant reduction of recurrent ischemia from 21% with
hrombolysis to 6% after primary PCI during short-term (p
0.0001), and also during long-term follow-up (39% vs.
2%, p  0.0001).
At the other side of the spectrum reside patients with a
hronic total occlusion (CTO), defined as a complete
cclusion at least 3 months old (3) (Table 1). In this setting,
he benefit from recanalization is time-independent and is
ased on relieving symptomatic ischemia and angina, en-
ancing left ventricular function, reducing predisposition to
entricular arrhythmias, and improving tolerance of con-
ralateral coronary occlusion. From a clinical standpoint,
TO recanalization is usually attempted in symptomatic
atients or in patients with evidence of silent ischemia in a
arge territory at risk and/or with the presence of viable
yocardium. In this regard, contrast and adenosine stress
agnetic resonance imaging may identify viable and isch-
mic myocardium subtended by a CTO that may benefit
rom revascularization (4). Several retrospective observa-
ional studies have reported the clinical impact of successful
ercutaneous CTO revascularization on long-term survival.
n a consecutive series of 2,007 patients undergoing in-
ended PCI of a nonacute coronary occlusion at the Mid
merica Heart Institute between 1980 and 1999 (5),
echnical success was achieved in 74.4%. Compared with
hose patients in whom the procedure was successful, the
n-hospital occurrence of major adverse cardiac events was
ignificantly higher among patients with procedural failure
3.2% vs. 5.4%; p 0.02). Long-term survival was similar in
atients with successful CTO recanalization compared with
hat seen in a matched cohort of patients undergoing
uccessful angioplasty of nonoccluded lesions and signifi-
antly greater than in patients in whom attempted CTO
evascularization failed (10-year survival 73.5% with CTO
uccess vs. 65.0% with CTO failure, p  0.001). By
ultivariate analysis, failure to successfully recanalize the
TO was an independent predictor of reduced survival
hazard ratio 1.4 [95% confidence interval (CI) 1.25 to 2.0],
 0.0003). In the prospective TOAST-GISE (Total
cclusion Angioplasty Study–Società Italiana di Cardiolo-
ia Invasiva) (6), successful PCI of a CTO (attempted in
90 lesions in 369 patients) was associated with a reduced
2-month incidence of cardiac death or MI (1.1% vs. 7.2%;
 0.005), a reduced need for coronary artery bypass
urgery (2.5% vs. 15.7%; p  0.0001), and greater freedom
rom angina (88.7% vs. 75.0%; p  0.008). In the overall
tudy population, the only factor associated with enhanced
-year event-free survival was successful CTO recanaliza-
ion (odds ratio [OR] 0.24 [95% CI 0.07 to 0.80], p 
.018). Finally, a total of 874 consecutive patients were
reated for 885 CTO lesions at the Thoraxcenter between
992 and 2002. Mean follow-up time was 4.47 2.69 years
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Editorial Comment March 4, 2008:965–7median 4.10 years). At 5 years, survival was significantly
igher in those patients with a successful revascularization
93.5% vs. 88.0%, p  0.02). Independent predictors for
urvival were successful revascularization, lower age, and the
bsence of diabetes mellitus and multivessel disease (7).
Thus, the current evidence supports recanalization of the
RA not only acutely after MI (12 h) but also in the chronic
hase (3 months) if symptoms, ischemia, or viability of the
ccluded vessel are present. It is, therefore, questioned whether
n invasive strategy may also be indicated on a continuum for
atecomers after MI (12 h but 3 months). The most
ecently published update of the American College of Cardi-
logy/American Heart Association/Society for Cardiovascular
ngiography Interventions (ACC/AHA/SCAI) guidelines
8) for PCI refers to this issue. Specifically, it is recommended
Class I, Level of Evidence: A) to perform PCI after successful
brinolysis or in patients not undergoing primary reperfusion
ithin the first 12 h, in patients with any of the following:
bjective evidence of recurrent MI, presence of moderate or
evere spontaneous or induced ischemia after the MI, and in
ardiogenic shock or hemodynamic instability. Besides, it is
easonable to perform routine late PCI after an MI (Class IIa)
n patients with left ventricular ejection fraction 0.40, heart
ailure, or serious ventricular arrhythmias. However, PCI of a
otally occluded IRA24 h after an ST-segment elevation MI
s not recommended (Class III, Level of Evidence: B) in
symptomatic patients with 1- or 2-vessel disease if they are
evascularization of the IRA: Different Scenarios
Table 1 Revascularization of the IRA: Different Scenarios
Duration of the Occlusion Indications
3 months
Early (12 h) All patients (primary PCI)
Late (12 h to 3 months) “Open Artery Hypothesis”
3 months
Chronic total occlusion Symptoms/ischemia/viability guided
revascularization
RA  infarct-related artery; PCI  percutaneous coronary intervention.
CC/AHA/SCAI and ESC Guidelines for Patients After Successfulibrinolysis and for Patients Not Undergoing Primary Reperfusion (L
Table 2 ACC/AHA/SCAI and ESC Guidelines for Patients AfterFibrinolysis and for Patients Not Undergoing Primary R
Clinical Condition ACC/AH
After successful fibrinolysis (up to 24 h)
independent of angina and/or
ischemia
No recommendation
Patients not undergoing reperfusion
(latecomers) or after fibrinolysis with
residual moderate-to-severe
ischemia (beyond 24 h)
PCI if applicable; Class
Latecomers (12 to 24 h) asymptomatic
and stable
No recommendation
Latecomers (24 h) with
hemodynamically significant stenosis
in a patent IRA
PCI may be considered
strategy (Class IIb, L
Latecomers (24 h) asymptomatic and
stable with totally occluded IRA,
without evidence of ischemia
PCI not recommended
Evidence: B)CC/AHA/SCAI  American College of Cardiology/American Heart Association/Society for Cardiovas
s in Table 1.emodynamically and electrically stable and do not have
vidence of severe ischemia. For those patients having received
hrombolysis before 24 h, these guidelines do not express any
ecommendation. However, the European Society of Cardiol-
gy (ESC) guidelines (1) recommend routine coronary angiog-
aphy and, if applicable, PCI early after effective thrombolysis
Class I, Level of Evidence: A) up to 24 h after thrombolysis
ndependent from angina and/or ischemia. For those patients
ot having received reperfusion (latecomers), the ESC guide-
ines do not express any recommendation due to inconsistent
ata at the time of the publication.
Taken together both guidelines are to some extent
omplementary but somewhat insufficient as they do not
over all possible scenarios and clinical situations in this
ime frame (Table 2). In this regard in this issue of the
ournal, Abbate et al. (9) should be commended for their
eta-analysis that has contributed to shed light on this
ontroversial topic. The authors retrieved 10 studies enroll-
ng 3,560 patients that were randomized to either late PCI
f the IRA (range 1 to 26 days after the MI) or optimal
edical treatment. The primary end point of this meta-
nalysis was all-cause mortality. In addition, left cardiac
emodeling was also assessed in those studies with echocar-
iographic analyses. Randomization allocated 1,779 subjects
o PCI and 1,781 to medical treatment. As a result, late PCI
mproved survival as compared with medical treatment (OR
.49 [95% CI 0.26 to 0.94], p  0.030) during a follow-up
eriod of 2.8 years (42 days to 10 years). This beneficial
ffect in all-cause mortality reduction was associated with
avorable effects on cardiac function and remodeling, as late
CI demonstrated significant greater improvement in left
entricular ejection fraction and left ventricular end diastolic
nd end systolic volume indexes. This meta-analysis fully
ddressed the open artery hypothesis with an adequate final
ample size and a long enough clinical follow-up. This
ypothesis suggests that survival after MI depends on the
ffect of mechanical recanalization to improve left ventric-
omers)
essful
usion (Latecomers)
AI ESC
Routine angiography and PCI if applicable;
Class I, Level of Evidence: A
l of Evidence: B PCI if applicable; Class I, Level of Evidence: B
No recommendation
f an invasive
Evidence: B)
No recommendation
III, Level of No recommendationatec
Succ
eperf
A/SC
I, Leve
part o
evel of
(Classcular Angiography Interventions; ESC  European Society of Cardiology; other abbreviations
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March 4, 2008:965–7 Editorial Commentlar remodeling and healing, to enhance electrical stability,
nd to cause myocardial perfusion rather than to reduce the
nfarct size (that is, myocardial salvage). Interestingly, this
eta-analysis did not include those trials aimed to deter-
ine whether performing routine PCI within the first 24 h
fter successful thrombolysis is beneficial as compared with
onventional medical treatment (10–13). As reflected in
able 2, the ESC guidelines gave, in this scenario, a Class
, Level of Evidence: A recommendation on the basis of the
randomized studies that addressed this issue: SIAM III
Southwest German Interventional Study in Acute Myocar-
ial Infarction) (10), GRACIA-1 (Randomized Trial Com-
aring Stenting Within 24 Hours of Thrombolysis Versus
schemia-Guided Approach to Thrombolysed Acute Myo-
ardial Infarction With ST Elevation) (11), CAPITAL-AMI
Combined Angioplasty and Pharmacological Intervention
ersus Thrombolysis Alone in Acute Myocardial Infarction)
12), and the Leipzig Prehospital Lysis study (13). On the
ontrary, the most recently updated ACC/AHA/SCAI guide-
ines do not mention this clinical situation. Probably, routine
ngiography post-effective thrombolysis does not reflect the
aradigm of the open artery hypothesis, as by definition most
RAs will be certainly open at the time of PCI. Then, to whom
oes this meta-analysis apply? Most of patients included in the
nalysis (84%) showed total IRA occlusion, and the presence of
elevant ischemia was an exclusion criterion in 6 of 10 studies.
esides, the degree of angiographic success was variable (range
2% to 100%) as were both the rates of stent implantation
range 0% to 100%) and the glycoprotein IIb/IIIa inhibitor
sage. In this heterogeneous scenario, poorly representative of
urrent PCI technology and outcomes, late PCI was still able
o significantly reduce the all-cause mortality rate. Another
nteresting finding was the fact that the benefit was more
bvious in those trials with a median follow-up of 4 years.
his goes in line with the hypothesis that restoration of
ntegrade blood flow to the peri-infarct area may interrupt the
rogression to apoptosis of the hibernating myocardium and
revent the development of cardiomyopathy (14,15).
Abbate et al. (9) have provided us with the last remaining
iece of evidence in the field of total occluded IRA. Finally,
ll gaps can be filled in (Table 2) by a homogenous
ecommendation and level of evidence. Successful PCI of
he nonreperfused IRA (beyond 12 h after the onset of
ymptoms) with or without the presence of ischemia is
ssociated with improved long-term survival and improved
ardiac function and remodeling parameters.
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